In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Low-Hanging Fruit for Medical Device Entrepreneurs

Executive Summary

In a speech at Windhover's December 2000 Start-Up Symposium, Novoste chairman Tom Weldon argued that device start-ups will be fewer and riskier. Both the FDA and physicians are demanding trials that prove clinical efficacy, raising the cost and therefore the risk of starting new companies. That means these firms will have to target larger markets, which by their very nature will require a change in medical practice and thus also a more expensive selling effort. Unless companies go after products that can sell a minimum of $500 million annually, financiers won't be able to justify the investment required to get these companies off the ground.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts